Tasquinimod Targets Suppressive Myeloid Cells in the Tumor Microenvironment

Overview

Journal Oncoimmunology

Specialty Allergy & Immunology

Date 2019 Oct 25

PMID 31646064

Citations 12

Authors

Li Shen

Roberto Pili

Affiliations

Soon will be listed here.

Abstract

Infiltrating myeloid derived suppressor cells and tumor-associated macrophages (TAMs) are important components of the immunosuppressive tumor microenvironment. We recently reported that tasquinimod, which binds to S100A9, impairs both infiltration and function of these cells. Here we discuss the underlying mechanisms responsible for targeting multiple suppressive populations and the modulation of the tumor microenvironment.

Citing Articles

2-Azidobenzaldehyde-Based [4+2] Annulation for the Synthesis of Quinoline Derivatives.

Zhang X, Liu M, Qiu W, Zhang W Molecules. 2024; 29(6).

PMID: 38542878 PMC: 10975811. DOI: 10.3390/molecules29061241.

S100A8/A9 predicts response to PIM kinase and PD-1/PD-L1 inhibition in triple-negative breast cancer mouse models.

Begg L, Orriols A, Zannikou M, Yeh C, Vadlamani P, Kanojia D Commun Med (Lond). 2024; 4(1):22.

PMID: 38378783 PMC: 10879183. DOI: 10.1038/s43856-024-00444-8.

: Pathogenesis and therapeutic targets.

Yang J, Zhang L, Qiao W, Luo Y MedComm (2020). 2023; 4(5):e353.

PMID: 37674971 PMC: 10477518. DOI: 10.1002/mco2.353.

S100A9 promotes glycolytic activity in HER2-positive breast cancer to induce immunosuppression in the tumour microenvironment.

Yuan J, Wang S, Guo L Heliyon. 2023; 9(2):e13294.

PMID: 36755606 PMC: 9900376. DOI: 10.1016/j.heliyon.2023.e13294.

Role of myeloid-derived suppressor cells in tumor recurrence.

Cole K, Al-Kadhimi Z, Talmadge J Cancer Metastasis Rev. 2023; 42(1):113-142.

PMID: 36640224 PMC: 9840433. DOI: 10.1007/s10555-023-10079-1.

References

Bjork P, Bjork A, Vogl T, Stenstrom M, Liberg D, Olsson A . Identification of human S100A9 as a novel target for treatment of autoimmune disease via binding to quinoline-3-carboxamides. PLoS Biol. 2009; 7(4):e97. PMC: 2671563. DOI: 10.1371/journal.pbio.1000097. View

Sica A, Bronte V . Altered macrophage differentiation and immune dysfunction in tumor development. J Clin Invest. 2007; 117(5):1155-66. PMC: 1857267. DOI: 10.1172/JCI31422. View

Sinha P, Okoro C, Foell D, Freeze H, Ostrand-Rosenberg S, Srikrishna G . Proinflammatory S100 proteins regulate the accumulation of myeloid-derived suppressor cells. J Immunol. 2008; 181(7):4666-75. PMC: 2810501. DOI: 10.4049/jimmunol.181.7.4666. View

Cheng P, Corzo C, Luetteke N, Yu B, Nagaraj S, Bui M . Inhibition of dendritic cell differentiation and accumulation of myeloid-derived suppressor cells in cancer is regulated by S100A9 protein. J Exp Med. 2008; 205(10):2235-49. PMC: 2556797. DOI: 10.1084/jem.20080132. View

Gabrilovich D, Nagaraj S . Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol. 2009; 9(3):162-74. PMC: 2828349. DOI: 10.1038/nri2506. View